Elicio Therapeutics announces departure of Chief Business Officer Annette Matthies effective Oct 19, 2023

Elicio Therapeutics, Inc.

Annette Matthies, Ph.D. ceased as Chief Business Officer; separation agreement signed October 19, 2023.
Company will pay six months of base salary and reimburse COBRA premiums for up to six months.
Separation includes standard release of claims and confidentiality covenants.
No replacement or successor has been named; reason for departure not disclosed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Annette Matthies

Chief Business Officer

ELTX · Elicio Therapeutics, Inc.

Effective: 2023-10-19
Filed: October 20, 2023, 7:59 PM ET

On October 19, 2023 , Elicio Therapeutics, Inc. (the “Company”) and Annette Matthies, Ph.D., former Chief Business Officer of the Company, entered into a Separation and Release Agreement

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Annette Matthies departed as Chief Business Officer at Elicio Therapeutics, Inc..

Action: ceased
Role: Chief Business Officer

Exact text from the filing

On October 19, 2023 , Elicio Therapeutics, Inc. (the “Company”) and Annette Matthies, Ph.D., former Chief Business Officer of the Company, entered into a Separation and Release Agreement

View on SEC.gov

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-23-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.